DCR-STAT3
/ Novo Nordisk
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
September 27, 2025
A Study of DCR-STAT3 in Adults With Solid Tumors
(clinicaltrials.gov)
- P1 | N=32 | Completed | Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Recruiting ➔ Completed
Trial completion • Solid Tumor
October 24, 2023
A Study of DCR-STAT3 in Adults With Solid Tumors
(clinicaltrials.gov)
- P1 | N=32 | Recruiting | Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
New P1 trial • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1